The EMPEROR [15] and DELIVER [16] trials demonstrated that, compared to placebo, sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce heart failure HF hospitalizations (HFH) and cardiovascular mortality by 21% and 18%, respectively. Here, SLC5A2 is linked to heart failure.